CRISPR Therapeutics
CRSP
52.35
-1.65
-3.06%
CRISPR Therapeutics
US · CRSP
#2057 by market cap
Listed 2016
52.35
-1.65
-3.06%
Live - 5344 symbols - heartbeat 151s ago
· 2026-10-08 08:38
Pre-market
51.51
-1.60%
After-hours
52.65
+0.57%
Overnight
52.09
-0.50%
- Market cap
- 5.06B
- P/E (TTM)i
- -11.11
- P/Bi
- 2.90
- EPSi
- -6.47
- Div yieldi
- 0.00%
- 52W posi
- 27%
Reader sentiment
Are you bullish or bearish on CRSP?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 3.1 percentage points.
Institutional ownership
- Held by institutions
- 78.76% -3.06pp
- Institutions
- 604 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund58.11%
Hedge Fund6.83%
VC/PE Fund6.70%
Public Company2.95%
Private Company1.92%
Government Pension Fund1.51%
Individual/Insider0.45%
Sovereign Wealth Fund0.30%
Family Office/Trust0.28%
Other20.94%
Top holders as of 2026-06-30
ARK Investment Management LLC
9.78% · 9.46M sh
BlackRock
8.63% · 8.35M sh
Capital Research
6.43% · 6.22M sh
Orbis Investment Management Limited
5.64% · 5.45M sh
State Street Global Advisors
4.47% · 4.32M sh
GSK Equity Investments, Limited
3.33% · 3.22M sh
Geode Capital Management, LLC
2.60% · 2.51M sh
T. Rowe Price Group, Inc.
2.26% · 2.18M sh
SR One Capital Management, LP
2.11% · 2.04M sh
Two Sigma Investments, LP
2.06% · 1.99M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 34 buys · 16 sells
| Name | Role | Stake |
|---|---|---|
| Samarth Kulkarni | Chairperson & CEO | 0.26% |
| James Kasinger | General Counsel | 0.10% |
| Douglas Treco | Lead Independent Director | 0.02% |
| Naimish Patel | Chief Medical Officer | 0.02% |
| Ali Behbahani | Independent Director | 0.02% |
| Raju Prasad | Chief Financial Officer | 0.02% |
| John Greene | Independent Director | 0.01% |
| Briggs Duncan W. Morrison | Independent Director | 0.01% |
| Katherine High | Independent Director | -- |
| Simeon George | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-21 | James Kasinger | General Counsel | Derivative Exercise and Sale | -10,400 | $13.62–60.24 |
| 2026-09-16 | Ali Behbahani | Independent Director | Derivative Exercise and Sale | -13,679 | $14.00–57.09 |
| 2026-09-16 | Ali Behbahani | Independent Director | Derivative Exercise and Retained | +16,321 | $14.00 |
| 2026-08-06 | Raju Prasad | Chief Financial Officer | Other Disposition | -750 | -- |
| 2026-06-04 | Douglas Treco | Lead Independent Director | Other Derivative Acquisition | +13,000 | $51.84 |
| 2026-06-04 | Katherine High | Independent Director | Other Derivative Acquisition | +13,000 | $51.84 |
| 2026-06-04 | Briggs Duncan W. Morrison | Independent Director | Other Derivative Acquisition | +13,000 | $51.84 |
| 2026-06-04 | Simeon George | Independent Director | Other Derivative Acquisition | +13,000 | $51.84 |
| 2026-06-04 | Christian Rommel | Independent Director | Other Derivative Acquisition | +13,000 | $51.84 |
| 2026-06-04 | Maria Fardis | Independent Director | Other Derivative Acquisition | +13,000 | $51.84 |
| 2026-06-04 | Sandesh Mahatme | Independent Director | Other Derivative Acquisition | +13,000 | $51.84 |
| 2026-06-04 | John Greene | Independent Director | Other Derivative Acquisition | +13,000 | $51.84 |
| 2026-06-04 | Harold Fleming | Independent Director | Other Derivative Acquisition | +13,000 | $51.84 |
| 2026-06-04 | Ali Behbahani | Independent Director | Other Derivative Acquisition | +13,000 | $51.84 |
| 2026-05-28 | Raju Prasad | Chief Financial Officer | Other Derivative Acquisition | +19,500 | -- |
| 2026-05-28 | Naimish Patel | Chief Medical Officer | Derivative Exercise and Sale | -3,786 | $55.62 |
| 2026-05-28 | Naimish Patel | Chief Medical Officer | Other Derivative Acquisition | +22,000 | -- |
| 2026-05-28 | James Kasinger | General Counsel | Other Derivative Acquisition | +17,000 | -- |
| 2026-05-27 | Naimish Patel | Chief Medical Officer | Derivative Exercise and Retained | +6,214 | -- |
| 2026-03-22 | Samarth Kulkarni | Chairperson & CEO | Derivative Exercise and Sale | -10,020 | $46.78 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:38:48 · For reference only, not investment advice and not tailored to your situation.